ACB · Aurora Cannabis

The thesis

Organigram Global's agreed C$7.80-per-share deal sets the value for Aurora Cannabis, and the shares trade below it, so a completed deal or a higher Curaleaf offer would pay out more than the closing price. Two things settle it: whether Curaleaf raises before its offer expires on 4 December 2026, and whether both companies' shareholders approve the Organigram deal at meetings expected in December 2026.

Aurora closed at $5.05 on 11 November 2026. Benzinga converted the C$7.80 offer to US$5.57 on 3 November 2026 (Benzinga). The shares have closed lower for three sessions running, from $5.24 on 6 November 2026. No new terms came from either bidder in that time.

Curaleaf has strengthened its position without raising its price. On 10 November 2026 it said all required competition clearances for its offer were in hand, in Canada and Germany (Curaleaf 8-K). It also pointed out that the Organigram deal still needs shareholder, court and regulatory approvals. The price the market pays for the shares still rests on the Organigram terms, with a higher Curaleaf offer as the upside.

Bullish and bearish views on Aurora Cannabis Inc.

The bull case on Aurora Cannabis Inc. (ACB), in brief: a signed, board-backed agreement exists. The bear case: part of the price floats with Organigram.

Bull case

• A signed, board-backed agreement exists. Aurora's 3 November 2026 release offers C$7.80 cash, 5.8626 Organigram shares, or C$3.75 cash plus 3.0431 Organigram shares per Aurora share, valuing fully diluted equity at about C$561 million (Aurora Form 6-K). Aurora's board recommends it unanimously.
• The cash is funded. British American Tobacco (BAT) agreed to buy 141.0 million Organigram shares at C$1.33 for about C$187.5 million to fund the cash portion, according to the same 3 November 2026 release.
• Curaleaf is still in the contest. Curaleaf chief executive Boris Jordan said on the 4 November 2026 earnings call that Curaleaf is "going to improve our bid substantially," naming no price (The Deep Dive). Curaleaf's 10 November 2026 release says its offer, amended on 6 October 2026, remains outstanding with competition clearances complete, which Curaleaf says may allow a faster close than Organigram's.
• The business kept growing through the contest. Aurora reported fiscal second-quarter net revenue of C$86.0 million on 5 November 2026, up 9% year over year, with record international medical revenue of C$61.4 million, up 44%, and C$133.0 million of cash and short-term investments with no debt (Aurora Form 6-K).

Bear case

• Part of the price floats with Organigram. The C$7.80 figure rests on Organigram's 20-day volume-weighted average price of about C$1.33 on 2 November 2026. Cash elections are prorated against a C$253,638,772 total, so an all-cash election may be partly paid in Organigram shares.
• Curaleaf's raise carries a condition. Coverage of the 4 November 2026 call reports Jordan called due diligence access an absolute condition for a material increase. Curaleaf's 3 November 2026 statement said Aurora gave Organigram that access and denied it to Curaleaf (Tobacco Reporter).
• A covering analyst favours the agreed deal. TD Cowen analyst Derek Lessard advised Aurora shareholders to accept Organigram's offer, citing greater certainty, and cut his target to C$7.80 to match it, Cantech Letter reported in November 2026 (Cantech Letter). A target pinned to the deal price leaves no analyst-implied value above it.
• Two votes and several approvals remain. Aurora needs two-thirds of votes cast plus a majority excluding interested holders; Organigram needs a simple majority excluding BAT's votes. Closing also needs British Columbia court approval, TSX approval and German foreign direct investment clearance, with closing expected in January 2027.
• The quarter's per-share result missed. Benzinga reported a fiscal second-quarter loss of $(0.32) per share against a $(0.09) estimate on 5 November 2026, and adjusted EBITDA (earnings before interest, taxes, depreciation and amortisation) fell to C$14.0 million from C$15.4 million.

Price setup

Aurora closed at $5.05 on 11 November 2026, after $5.24 on 6 November 2026, $5.16 on 9 November 2026 and $5.11 on 10 November 2026. The shares are up 33.2% over three months from the $3.79 close of 13 August 2026. The 52-week high is $6.36, set intraday on 18 December 2025, and the last close is 20.6% below it. The 52-week closing low is $2.58 on 16 July 2026.

The 50-day moving average is $4.21 and the 200-day moving average is $3.57, both as of 11 November 2026. The 50-day average still sits close to where the shares traded before Organigram's agreement, so a slide to that average would mean the market had stopped pricing the Organigram terms.

The shares now trade on deal terms. Their value follows Organigram's TSX price, the Canadian dollar against the US dollar, and the odds of a higher Curaleaf offer. A close back toward the US$5.57 conversion of 3 November 2026 would show the market pricing completion with little discount; a widening gap would show doubt about the votes, the Organigram share price or the contest.

Catalysts ahead

• 4 December 2026: Scheduled expiry of Curaleaf's amended offer for Aurora, unless withdrawn or amended. Shows whether Curaleaf raises, extends or lets the offer lapse, and so whether the contest can lift the price above Organigram's terms.
• December 2026 (date not set): Special meetings of Aurora and Organigram shareholders on the arrangement. Aurora needs two-thirds approval plus a majority excluding interested holders; Organigram needs a majority excluding BAT's votes. A failed vote at either company ends the deal.
• January 2027 (company expectation): Expected closing of the Organigram deal. Closing depends on the votes, court approval, TSX approval and German foreign direct investment clearance, and fixes what Aurora shareholders finally receive.

What would change the view

A daily close below $4.15, the 27 October 2026 close from before Organigram's agreement, which would show the market pricing a failed deal. Termination of the Organigram agreement with no higher offer in its place, or a failed Aurora or Organigram shareholder vote, would also show the case failing.

The risks this note tracks, each with what would confirm it:

• Curaleaf does not raise, removing the chance of a price above Organigram's terms. Confirmed by: Curaleaf's offer expiring or being withdrawn around 4 December 2026 with no increase, or Curaleaf saying it has ended its pursuit.
• Organigram's share price falls, lowering the value of the share component of the deal. Confirmed by: Organigram's TSX price trading below the C$1.33 reference average with the exchange ratios unchanged.
• Organigram shareholders reject the share issuance or private placement. Confirmed by: a failed vote at Organigram's December 2026 meeting, with British American Tobacco's votes excluded from the count.
• Regulatory or court conditions delay or block completion of the Organigram deal. Confirmed by: German foreign direct investment clearance or British Columbia court approval slipping past the January 2027 closing expectation or being refused.
• Proration leaves shareholders with less cash than they elect. Confirmed by: cash elections above the C$253,638,772 total, as disclosed after the election deadline.
• A weaker Canadian dollar lowers the US-dollar value of the Canadian-dollar deal terms. Confirmed by: the Canadian dollar falling against the US dollar between now and the January 2027 expected closing.

What it trades with

Aurora's shares now move mainly with Organigram's share price and the Canadian dollar, and only loosely with the S&P 500. A higher Curaleaf offer would tie part of the value to Curaleaf's subordinate voting shares, which trade on the TSX and OTCQX and respond to US cannabis policy news. Aurora itself has no US THC operations.